Contact

Biotech investment analysis. ABAC Therapeuthics raises €16M.


, , , , , , , ,
Integral service around a transaction
BY : Diego GutiérrezMarch Mon, 2018

Find out about the latest investment rounds in the European biotech sector in 2018. In addition, we analyse the investment round of ABAC Therapeutics, which has received a capital injection of €16M.

Find out about the latest investment rounds in the European biotech sector in 2018. In addition, we analyse the investment round of ABAC Therapeutics, which has received a capital injection of €16M.

About ABAC Therapeutics

ABAC Therapeutics is a company specialising in the development of therapeutic solutions for patients infected with highly antibiotic-resistant bacterial pathogens, leaving them with few (or no) treatment options.

The company, based in Esplugues de Llobregat (Barcelona), uses its proprietary drug discovery platform PasNas to identify novel antibiotics to combat multi-resistant bacteria.

ABAC is currently developing an antibiotic against Acinetobacter baumannii, a deadly bacterium which, according to the World Health Organisation (WHO), is the main pathogenic threat for which there is no treatment. According to CEO Albert Palomer, the company has chosen this bacterium because of its high mortality rate: 50% of infected patients die.

ABAC Therapeutics, spin off of Ferrerwas founded in 2014 as part of its new open innovation strategy.

ABAC Therapeutics closes €16M investment round

ABAC Therapeutics, dedicated to researching new pathogen-specific antibiotics, has closed a €16M funding round.

This capital injection was led by Pontifax, an Israeli fund that invests in healthcare companies; Global Health Science Fund (the Global Health Science Fund, created jointly by Quark Venture Inc. and GF Securities); Caixa Capital Risc; Debiopharm Innovation Fund and the pharmaceutical company Ferrer, which have joined ABAC's board of directors.

The funds raised will be used to successfully complete the phase I clinical trial of its drug Abac-39877, currently a pre-clinical candidate in the fight against Acinetobacter baumannii, and then seek a licensing agreement.

When it was founded as a spin-off from Ferrer, ABAC's capital was divided into 80% for the pharmaceutical company and 20% for Palomares and Gargallo. With the new partners, the capital is divided almost equally into five parts.

 

Latest Biotech investment rounds in 2018

 

PROGRAMMEGLOBAL LEHIAN 2018
PUBLIC BODYBASQUE GOVERNMENT - Department of Economic Development and Infrastructures.
BENEFICIARIESMicro, small and medium-sized enterprises (SMEs), individually or in cooperation, located in the Autonomous Community of the Basque Country, and which have an internationalisation plan in force.
PURPOSE OF THE PROGRAMMESupport for the internationalisation of individual and cooperative SMEs.
CHARACTERISTICS OF THE AIDELIGIBLE EXPENDITURE:

INITIATION STAGE - Drawing up of the Internationalisation Plan (external advice may be contracted to carry out a diagnosis and/or to draw up an Internationalisation Plan), travel, visits to trade fairs and the preparation of agendas. In the case of cooperative projects, feasibility studies and incorporation costs are also financed.

CONSOLIDATION STAGE - Prospecting trips, visits to trade fairs, reverse missions, invitations to potential clients, participation in trade fairs, promotional material, advertising, feasibility studies of implementation projects.

IMPLANTATION STAGE - Incorporation costs, structure costs, travel costs between parent company and the implanted company, promotion costs.

STAGE ACTIVATION OF TALENT AND ADAPTATION OF ORGANISATIONS TO THE GLOBAL MARKET - Recruitment costs for technical specialists or managers.


TRAVEL BAGS:

INITIATION STAGE - 7 travel bags per application.

CONSOLIDATION STAGE - 5 travel bags per country, with a maximum of 3 countries per application.

IMPLANTATION STAGE - 7 travel bags per application between parent and implanted company; countries other than the location of the parent company or the implanted company will not be accepted as origin or destination in this call.

In the case of participation in trade fairs abroad with a stand and presentation of products, travel bags shall not count towards the above-mentioned maximums.


INVITATIONS TO POTENTIAL FOREIGN CUSTOMERS AND/OR SUPPLIERS:

In the consolidation phase the maximum number of invitations per request shall be 9, provided that they occur in different months.
For each invitation, the limit for accommodation and transport costs referred to in Article 4 of the Order is 600,00€.
COMPATIBLE with other aid.
TYPES OF AIDGRANT: The total limit of support per beneficiary per year is €50,000.


LIMITS - INDIVIDUAL PROJECTS:

Initiation stage - up to 40% - max €20,000.
Consolidation phase - up to 40% - max €30,000.
Implementation phase - up to 40% - max 40.000€.
Talent activation stage - up to 50% - max €20,000.


LIMITS - COOPERATION PROJECTS:

Start-up and Consolidation Stage - Sales and Promotion Groups up to 50% with a maximum of €12,000 per company and €40,000 overall.
Start-up and consolidation stage - Export Consortia at Origin up to 50% with a maximum of €14,000 per company and €40,000 overall.
Talent Activation Stage - Export Consortia - 50% managerial recruitment costs up to a limit of €30,000.
DEADLINENEXT OPENING
- 23 MARCH 2018 AT 12:00 NOON.

For the elaboration of the Internationalisation Plan - 26 APRIL 2018 AT 12:00 NOON.
INFORMATION+34 946 42 41 42

info@abra-invest.com

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu